Progression-free Survival after first Metastasectomy | Disease-free Survival after Liver-directed therapy (LDT) | ||||
---|---|---|---|---|---|
Variables | n | Median Time (months) with IQR | p-value | Median Time (months) with IQR | p-value |
Gender | |||||
Male | 24 | 8 (5–44) | 0.324 | 15 (5–44) | 0.346 |
Female | 11 | 27 (10–47) | 20 (9–58) | ||
Targeted therapy | |||||
TKI+ | 16 | 47 (18–79) | 0.023 | 58 (18–79) | 0.110 |
TKI– | 19 | 19 (6–39) | 19 (4–46) | ||
ECOG | |||||
0 | 29 | 29 (10–47) | 0.015 | 20 (8–71) | 0.132 |
> 1 | 6 | 6 (2–28) | 15 (1–28) | ||
Age | |||||
< 65 years | 18 | 19 (8–40) | 0.518 | 19 (5–71) | 0.960 |
> 65 years | 17 | 39 (8–71) | 20 (9–58) | ||
Tumor distribution | |||||
unilobular | 28 | 28 (8–44) | 0.772 | 28 (8–58) | 0.981 |
multilobular | 7 | 19 (3–77) | 19 (3–79) | ||
Extrahepatic Disease | |||||
Yes | 28 | 27 (7–45) | 0.412 | 19 (8–59) | 0.962 |
No | 7 | 29 (4–82) | 20 (4–29) | ||
Liver metastasis Timing | |||||
Synchronous | 6 | 4 (2–9) | 0.035 | 4 (2–8) | 0.085 |
Metachronous | 29 | 28 (10–47) | 26 (12–58) | ||
Tumor size, cm | |||||
< 4.5 cm | 21 | 39 (10–71) | 0.07 | 19 (9–42) | 0.376 |
> 4.5 cm | 14 | 18 (6–29) | 18 (5–35) | ||
Resection margin | |||||
Radical resection (R0) | 30 | 28 (12–51) | 0.001 | 28 (12–58) | 0.014 |
Irradical resection (R1/R2) | 5 | 6 (3–10) | 4 (3–9) | ||
Number of metastases | |||||
Solitary | 22 | 27 (8–47) | 0.653 | 28 (9–51) | 0.967 |
Multiple | 13 | 19 (8–40) | 19 (5–79) | ||
Grading of RCC | |||||
Low (G1/G2) | 24 | 40 (18–71) | 0.002 | 44 (18–71) | 0.001 |
High (G3/G4) | 11 | 8 (5–19) | 8 (4–19) | ||
T-stage | |||||
T1/T2 | 16 | 44 (12–79) | 0.027 | 29 (15–71) | 0.071 |
T3/T4 | 19 | 18 (6–39) | 18 (4–51) | ||
Disease-free intervall | |||||
< 12 months | 17 | 28 (5–79) | 0.753 | 28 (5–79) | 0.501 |
> 12 months | 18 | 27 (10–40) | 19 (9–58) |